SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.
Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.
Keranova S.A. is a French start-up established in 2015, specializing in the design and development of surgical equipment for ophthalmologic applications, specifically targeting the anterior segment of the eye. Headquartered in Saint Etienne, with an additional office in Vénissieux, the company focuses on creating innovative medical technologies. Keranova's teams are dedicated to advancing ophthalmic procedures through the development of novel surgical instruments that incorporate a unique patented technology, marking significant improvements in the effectiveness and efficiency of eye surgeries.
Private Equity Round in 2019
Doc Generici s.r.l. is a Milan-based pharmaceutical company that specializes in the production and distribution of generic medicines in Italy. Established in 1996, the company offers a wide range of therapeutic products, including anti-infective, anti-neoplastic, cardiovascular, dermatological, hematological, gastrointestinal, neurological, ophthalmology, respiratory, musculoskeletal, and genitourinary drugs, along with systemic hormonal preparations. Additionally, it provides nutritional supplements and medical devices. Doc Generici became a key player in the market following the implementation of legislation that mandated the provision of lower-priced equivalent medicines by pharmacists. The company is a subsidiary of Diocle S.p.A. and was acquired in 2013 by Charterhouse Capital Partners LLP, enabling it to maintain its independence and focus on high-quality generic manufacturing in Europe, particularly in Italy.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Private Equity Round in 2018
Biobest N.V. develops and supplies natural crop care systems. It specializes in bumblebee pollination and sustainable crop management. The company offers biological pollination products, such as bumblebees; biological control products, which include beneficial insects and mites, beneficial nematodes, and biopesticides; and monitoring and scouting products, including sticky traps and rolls, pheromone traps, and pheromone lures and attractants to growers.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, non-aqueous formulations of peptides, proteins, and small molecules via subcutaneous and intramuscular routes. These formulations can be administered using standard delivery devices such as syringes, auto-injectors, and infusion pumps. Xeris Biopharma's lead product is Gvoke HypoPen, designed for treating severe hypoglycemia in diabetes patients. Other product candidates include a ready-to-use glucagon formulation and a diazepam formulation in clinical trials for conditions such as post-bariatric hypoglycemia and Dravet syndrome, respectively. The company aims to enhance patient care by simplifying the administration process and improving product stability, thereby reducing healthcare costs. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma serves patients, caregivers, and healthcare practitioners.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Stiplastics S.A.S. engages in designing, developing, and manufacturing medical devices for the healthcare industry
Laboratoires Ineldea, founded in 2003 and based in Carros, France, specializes in the formulation, development, manufacturing, and marketing of nutritional and health supplements, organic cosmetics, and healthcare products. The company benefits from over 20 years of experience in natural products and possesses recognized technical and scientific expertise in innovative natural health solutions. With a diverse portfolio of over 400 products, Ineldea consistently introduces several innovations each year, earning the trust of healthcare professionals and consumers alike. Their offerings are designed to meet the specific health needs of individuals at various life stages, including men, women, children, and athletes. Laboratoires Ineldea markets its products internationally through pharmacies, drugstores, specialty stores, and health professionals.
PhysioAssist, founded in 2012, specializes in developing innovative medical devices aimed at treating obstructive respiratory diseases. The company's patented technology modifies the physical properties of mucus, facilitating the mobilization and removal of secretions to enhance airway clearance. This approach provides healthcare professionals and patients with effective solutions for managing bronchial congestion, ultimately improving the quality of life for those suffering from respiratory conditions. The design and ergonomics of PhysioAssist's devices have been carefully optimized to ensure they are suitable for daily use in patient care settings.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, non-aqueous formulations of peptides, proteins, and small molecules via subcutaneous and intramuscular routes. These formulations can be administered using standard delivery devices such as syringes, auto-injectors, and infusion pumps. Xeris Biopharma's lead product is Gvoke HypoPen, designed for treating severe hypoglycemia in diabetes patients. Other product candidates include a ready-to-use glucagon formulation and a diazepam formulation in clinical trials for conditions such as post-bariatric hypoglycemia and Dravet syndrome, respectively. The company aims to enhance patient care by simplifying the administration process and improving product stability, thereby reducing healthcare costs. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma serves patients, caregivers, and healthcare practitioners.
Ivantis Inc. is dedicated to developing innovative treatments for primary open angle glaucoma, a condition affecting over 60 million people globally. The company has created an intracanalicular scaffold or implantable device designed to alleviate high intraocular pressure in patients, offering a less invasive and more effective therapeutic option. Founded in 2007 and based in Irvine, California, Ivantis also provides a Session Persistence Server, which safeguards telnet task workers against data loss due to network issues and ensures terminal emulation users maintain productivity across various devices and operating systems. As Ivantis advances its glaucoma treatment solutions, it aims to expand its focus to other debilitating ophthalmic diseases. The company primarily serves ophthalmology specialists in the United States, providing its solutions for use in clinical trials.
LNA Sante is a global health player with nearly 70 establishments in France and Belgium. Nursing homes (EHPAD and MRS), Follow-up care and rehabilitation (SSR), Home hospitalization structures (HAD), Health centers, Psychiatric clinic. Our mission is to improve the quality of life for people who are temporarily or permanently vulnerable, in a welcoming and caring environment, suitable for everyone and for all ages. Our commitment "To care and take care" of you or your loved ones daily, patients and residents who are welcomed in our structures in France or in Belgium. A mission and commitment shared by all our teams.
Private Equity Round in 2016
Seqens is a integrated in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to our customers.
Keranova S.A. is a French start-up established in 2015, specializing in the design and development of surgical equipment for ophthalmologic applications, specifically targeting the anterior segment of the eye. Headquartered in Saint Etienne, with an additional office in Vénissieux, the company focuses on creating innovative medical technologies. Keranova's teams are dedicated to advancing ophthalmic procedures through the development of novel surgical instruments that incorporate a unique patented technology, marking significant improvements in the effectiveness and efficiency of eye surgeries.
Private Equity Round in 2016
Novacap is a leading manufacturer and distributor of essential chemicals for use in everyday products. We have a very wide range of products among which salicylic acid and aspirin for which we are the worldwide leader, paracetamol and para-aminophenol, soda ash and sodium bicarbonate, phenol and oxygenated solvents, hydrochloric acid and derivatives which are used in growing end-markets such as pharmaceutical & healthcare, food & feed, cosmetics & fragrances, home care and environment. Construction and automotive markets are historical markets for which we are also a reference partner.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs. It strives to fulfill its mission of supplying everything a researcher needs for gene based research. Through licensing and selling research materials including genes, proteins, and research tools, it enables critical biological research.
keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.
Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging to enhance patient selection and monitor treatment progress for cancer immunotherapy. Founded in 2007 and headquartered in Inglewood, California, the company develops highly targeted diagnostic imaging agents based on engineered antibody fragments, known as minibodies. These minibodies are designed to image specific molecular targets using standard Positron Emission Tomography (PET) technology. ImaginAb's portfolio includes precision imaging products such as CD8 (IAB22M2C) and CD4 for immune-oncology applications, as well as PSMA PET (IAB2M) for prostate cancer. The company’s innovative platform technology allows for the rapid engineering of these antibody fragments, optimizing them for clinical imaging while maintaining their specificity and effectiveness in addressing the diagnostic needs in oncology.
Kalila Medical is developing a novel platform of specialized catheters for vascular and intracardiac access. The company’s initial product offering includes a family of steerable sheaths for use during catheter based atrial fibrillation ablation. Compatible with 8Fr and 12Fr ablation catheters, the Kalila sheath provides superior torque and tip control during catheter delivery and lesion formation . Founded in 2010, Kalila Medical is the third of a portfolio of companies to be formed out of Shifamed LLC (www.shifamed.com), a Silicon Valley based medical device incubator. Kalila Medical – Redefining precision and control
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
HumanCharger is a bright light therapy device that has a unique and patented mechanism of action which stimulates the photosensitive proteins on the surface of the brain using a calibrated white light that passes through the ear canals. Using the HumanCharger® for only 12 minutes a day can significantly increase your energy levels, improve mood and increase your mental alertness.
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory, through 50 agencies.
Private Equity Round in 2013
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory, through 50 agencies.
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
Biom'Up S.A. develops and commercializes hemostatic products based on patented biopolymers. It offers HEMOBLASTTM bellows and its laparoscopic applicators to simplify the surgeons’ practices for open surgical procedures in various specialties, such as cardiac, general and orthopedic, and laparoscopic surgeries. The company markets its products in Europe and the United States. Biom'Up S.A. was founded in 2005 and is based in Saint-Priest, France.
Advencis
Private Equity Round in 2012
Advencis is a developer and manufacturer of lab instruments and medical devices.The company has developed Advencis Bio-System Incubator, a modular system of early detection which is fully automated for industrial microbiology (food and pharmaceutical industries) and clinical markets. The system provides highly sensitive detection of the microorganisms on agar plates and on filter-based devices. It also provides Advencis Bio-System Software which is a real time monitoring application.
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.
Proclara Biosciences, Inc. is a biotechnology company focused on developing fusion-protein drug candidates for treating chronic neurodegenerative diseases, including Alzheimer's, Parkinson's, and other protein misfolding disorders. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform aimed at modifying disease progression. Proclara's therapies target and recognize multiple misfolded proteins, which may significantly improve outcomes for patients suffering from these debilitating conditions. The company's leading drug candidate, NPT001, is designed to disaggregate existing amyloid plaques associated with Alzheimer's disease, and it has shown promise in preclinical animal models. Proclara's innovative approach seeks to address the urgent medical needs of patients with neurodegenerative diseases and systemic amyloidosis.
QuantaLife, Inc. was formed to develop, manufacture and market a revolutionary nucleic acid testing concept for the Life Science Research, Clinical Molecular Diagnostics, Personalized Medical Care and Industrial markets. Our suite of products, which are based on our proprietary nucleic acid testing method, will enable rapid detection and quantification of nucleic acids in complex samples on a flexible, automated instrument. This technology provides an order of magnitude improvement in performance over current platforms at a fraction of the cost. QuantaLife is a small biotechnology startup involved in the early development phases of the technology.
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.